AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88

AbbVie Inc.

Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.
Adjusted diluted EPS guidance for Q4 2024 revised to $2.06-$2.10 (from $2.94-$2.98).
Full-year 2024 adjusted diluted EPS guidance revised to $10.02-$10.06 (from $10.90-$10.94).
Previous guidance excluded Q4 IPR&D expense; company does not forecast such expenses.
Q4 2024 results not finalized; subject to closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.